ABSTRACT
BACKGROUND: Acute myeloid leukemia (AML) is characterized by a complex spectrum of coagulopathy ranging from hemorrhagic to thrombotic symptoms. To date, platelet count (PLT) and conventional coagulation tests (CCTs) cannot predict hemorrhagic events and thrombotic risk. Thromboelastography (TEG) measures the viscoelastic properties of the clot, thus providing information on the entire process of blood coagulation. The primary aim of the study was to assess the hemostatic balance from AML diagnosis to the end of chemotherapy (CHT) by TEG. MATERIAL AND METHODS: Here we present the results of a prospective study enrolling newly diagnosed AML patients treated with chemotherapy. Patients had complete blood counts (CBCs), TEG and CCTs performed at three time points: 1) diagnosis (T0); 2) during the first cycle of CHT (T1); and 3) at the end of CHT (T2). An algorithm of TEG indirectly calculated thrombin generation (TG). Patients underwent daily follow-up for bleeding and thrombotic episodes up to the time of hospital discharge or death. RESULTS: Eighty consecutive patients were evaluated; forty were eligible for the study, and 21 completed the entire study. At T1, maximum amplitude (MA), TG and K-time were significantly shifted toward a hypocoagulability state compared to T0 (p<0.05), while a hypercoagulable state at T2 was shown by changes in α-angle, MA and TG values. Otherwise, there were no statistically significant differences in CCTs between the evaluated time points. DISCUSSION: Overall, TEG revealed complex and dynamic coagulation abnormalities in patients with AML according to both the course of disease and therapy. Further studies are needed to investigate more fully the role of TEG in defining the hemostatic profile in patients with AML.
Subject(s)
Blood Coagulation Disorders , Hemostatics , Leukemia, Myeloid, Acute , Thrombosis , Humans , Prospective Studies , Hemostasis , Blood Coagulation Tests/methods , Thrombelastography/methods , Hemorrhage/etiologyABSTRACT
Thromboembolic and bleeding events pose a severe risk for patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET). Many factors can contribute to promoting the thrombotic event due to the interaction between platelets, leukocytes, and endothelium alterations. Moreover, a significant role can be played by cardiovascular risk factors (CV.R) such as cigarette smoking habits, hypertension, diabetes, obesity and dyslipidemia. In this study, we evaluated the impact that CV.R plays on thrombotic risk and survival in patients with PV and ET.
ABSTRACT
Cardiovascular (CV) adverse events are considered common complications of ponatinib treatment. Recently, it has been demonstrated that ponatinib dose reductions in definite settings can obtain optimal responses and lower ponatinib-related CV events. In this study, we describe the management of 5 patients with chronic myeloid leukemia treated with ponatinib, from second to fourth line of tyrosine kinase inhibitor therapy, carrying high pre-ponatinib CV risk, who obtained optimal molecular response and developed no CV adverse event during follow-up. Among these 5 patients, 2 had diagnosis of ischemic heart disease and underwent percutaneous angioplasty, 2 had type 2 diabetes and arterial hypertension, and 1 had only arterial hypertension. Median follow-up for ponatinib therapy is 1,039 days (34.6 months). Median dosage administered is 30 mg a day. SCORE charts were used to estimate risk of CV death in 10 years and Charlson Comorbidity Index was applied to estimate age-adjusted risk of death related to comorbidities. Strict cardiologic follow-up (complete evaluation every 3 to 6 months) and maximum effort in the control of CV modifiable risk factors are strongly recommended in the management of ponatinib treatment in patients at high risk for CV events and may allow the use of ponatinib in patients belonging to CV risk category.
Subject(s)
Imidazoles/therapeutic use , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Protein Kinase Inhibitors/therapeutic use , Pyridazines/therapeutic use , Aged , Cardiovascular Diseases/etiology , Comorbidity , Female , Humans , Imidazoles/adverse effects , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/complications , Male , Middle Aged , Protein Kinase Inhibitors/adverse effects , Pyridazines/adverse effects , Risk Factors , Treatment OutcomeABSTRACT
OBJECTIVE: The analysis of scientific production in Puerto Rico is largely unexplored. The main aim of this study is to present the characteristics and trends of cancer publications in Puerto Rico's biomedical journals and their relationship with the island's cancer mortality. METHODS: A PubMed and a hard-copy search were performed to retrieve cancer-related articles published in the Puerto Rico Health Sciences Journal and the Boletín de la Asociación Médica de Puerto Rico from 1903 to 2005. Bibliometric indicators studied included the number of authors and references by article, first author's institutional affiliation and country, document type, and language. The study type and tumor classification were also recorded. Cancer proportional mortality (M%) in Puerto Rico and the proportion of cancer-related articles (P%) published were also evaluated. The annual percent change (APC) was estimated to assess trends. RESULTS: A total of 369 articles were retrieved. The institutions with the majority of publications were universities (39.6%), English was the predominant publication language (72.1%), and the principal document type was original papers (69.6%). Epidemiologic studies were the dominant study type (62.1%), and the most studied cancers were digestive (15.4%) and gynecologic (9.6%). Although the P% has increased since 1913 (APC = 1.2%), the M% increased at a faster pace (APC = 2.7%). CONCLUSIONS: Although a growth in the number of cancer publications is observed in these journals, it does not parallel the increase in proportional mortality. A better understanding of the cancer publications in Puerto Rico is essential to establish priorities, define future areas of research, and develop cancer control strategies.
Subject(s)
Bibliometrics , Biomedical Research , Neoplasms/mortality , Publishing/statistics & numerical data , Humans , Puerto RicoABSTRACT
OBJECTIVE: The analysis of scientific production in Puerto Rico is largely unexplored. The main aim of this study is to present the characteristics and trends of cancer publications in Puerto Rico's biomedical journals and their relationship with the island's cancer mortality. METHODS:A PubMed and a hard-copy search were performed to retrieve cancer-related articles published in the Puerto Rico Health Sciences Journal and the Boletín de la Asociación Médica de Puerto Rico from 1903 to 2005. Bibliometric indicators studied included the number of authors and references by article, first author's institutional affiliation and country, document type, and language. The study type and tumor classification were also recorded. Cancer proportional mortality (M percent) in Puerto Rico and the proportion of cancer-related articles (P percent) published were also evaluated. The annual percent change (APC) was estimated to assess trends. RESULTS:A total of 369 articles were retrieved. The institutions with the majority of publications were universities (39.6 percent), English was the predominant publication language (72.1 percent), and the principal document type was original papers (69.6 percent). Epidemiologic studies were the dominant study type (62.1 percent), and the most studied cancers were digestive (15.4 percent) and gynecologic (9.6 percent). Although the P percent has increased since 1913 (APC = 1.2 percent), the M percent increased at a faster pace (APC = 2.7 percent). CONCLUSIONS: Although a growth in the number of cancer publications is observed in these journals, it does not parallel the increase in proportional mortality. A better understanding of the cancer publications in Puerto Rico is essential to establish priorities, define future areas of research, and develop cancer control strategies.
OBJETIVO: El análisis de la producción científica de Puerto Rico está aún en gran parte pendiente. El objetivo principal de este estudio es presentar las características y las tendencias de las publicaciones sobre cáncer en las revistas biomédicas de Puerto Rico y su relación con la mortalidad por cáncer en la Isla. MÉTODOS: Se realizó una búsqueda en PubMed y revistas impresas para localizar los artículos relacionados con cáncer publicados entre 1903 y 2005 en Puerto Rico Health Sciences Journal y el Boletín de la Asociación Médica de Puerto Rico. Entre los indicadores bibliométricos estudiados están el número de autores y referencias por artículo, la afiliación institucional y el país del primer autor, el tipo de documento y el idioma; se recogió también el tipo de estudio y de cáncer. Se evaluaron la mortalidad proporcional por cáncer (M por ciento) en Puerto Rico y la proporción de artículos publicados relacionados con el cáncer (P por ciento). Para evaluar las tendencias se estimó el cambio porcentual anual (APC). RESULTADOS: Se localizaron 369 artículos. Predominaron los artículos originales (69,6 por ciento), de universidades (39,6 por ciento) y en inglés (72,1 por ciento). Los estudios epidemiológicos fueron los más frecuentes (62,1 por ciento) y los tipos de cáncer más estudiados fueron los del sistema digestivo (15,4 por ciento) y los ginecológicos (9,6 por ciento). Aunque el valor de P por ciento ha aumentado desde 1913 (APC = 1,2 por ciento), el valor de M por ciento aumentó más rápidamente (APC = 2,7 por ciento). CONCLUSIONES: Aunque se observó un incremento en el número de publicaciones sobre cáncer en estas revistas, este no se correspondió con el aumento en la mortalidad proporcional por esta causa. Es imprescindible comprender mejor lo relacionado con la publicación científica sobre cáncer en Puerto Rico para establecer prioridades, definir áreas futuras de investigación y desarrollar estrategias para el control del cáncer.